TY - JOUR
T1 - Pediatric Contact Dermatitis Registry Inaugural Case Data
AU - Goldenberg, Alina
AU - Mousdicas, Nico
AU - Silverberg, Nanette
AU - Powell, Douglas
AU - Pelletier, Janice L.
AU - Silverberg, Jonathan I.
AU - Zippin, Jonathan
AU - Fonacier, Luz
AU - Tosti, Antonella
AU - Lawley, Leslie
AU - Wu Chang, Mary
AU - Scheman, Andrew
AU - Kleiner, Gary
AU - Williams, Judith
AU - Watsky, Kalman
AU - Dunnick, Cory A.
AU - Frederickson, Rachel
AU - Matiz, Catalina
AU - Chaney, Keri
AU - Estes, Tracy S.
AU - Botto, Nina
AU - Draper, Michelle
AU - Kircik, Leon
AU - Lugo-Somolinos, Aida
AU - Machler, Brian
AU - Jacob, Sharon E.
N1 - Publisher Copyright:
Copyright © 2016 American Contact Dermatitis Society.All Rights Reserved.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background Little is known about the epidemiology of allergic contact dermatitis (ACD) in US children. More widespread diagnostic confirmation through epicutaneous patch testing is needed. Objective The aim was to quantify patch test results from providers evaluating US children. Methods The study is a retrospective analysis of deidentified patch test results of children aged 18 years or younger, entered by participating providers in the Pediatric Contact Dermatitis Registry, during the first year of data collection (2015-2016). Results One thousand one hundred forty-two cases from 34 US states, entered by 84 providers, were analyzed. Sixty-five percent of cases had one or more positive patch test (PPT), with 48% of cases having 1 or more relevant positive patch test (RPPT). The most common PPT allergens were nickel (22%), fragrance mix I (11%), cobalt (9.1%), balsam of Peru (8.4%), neomycin (7.2%), propylene glycol (6.8%), cocamidopropyl betaine (6.4%), bacitracin (6.2%), formaldehyde (5.7%), and gold (5.7%). Conclusions This US database provides multidisciplinary information on pediatric ACD, rates of PPT, and relevant RPPT reactions, validating the high rates of pediatric ACD previously reported in the literature. The registry database is the largest comprehensive collection of US-only pediatric patch test cases on which future research can be built. Continued collaboration between patients, health care providers, manufacturers, and policy makers is needed to decrease the most common allergens in pediatric consumer products.
AB - Background Little is known about the epidemiology of allergic contact dermatitis (ACD) in US children. More widespread diagnostic confirmation through epicutaneous patch testing is needed. Objective The aim was to quantify patch test results from providers evaluating US children. Methods The study is a retrospective analysis of deidentified patch test results of children aged 18 years or younger, entered by participating providers in the Pediatric Contact Dermatitis Registry, during the first year of data collection (2015-2016). Results One thousand one hundred forty-two cases from 34 US states, entered by 84 providers, were analyzed. Sixty-five percent of cases had one or more positive patch test (PPT), with 48% of cases having 1 or more relevant positive patch test (RPPT). The most common PPT allergens were nickel (22%), fragrance mix I (11%), cobalt (9.1%), balsam of Peru (8.4%), neomycin (7.2%), propylene glycol (6.8%), cocamidopropyl betaine (6.4%), bacitracin (6.2%), formaldehyde (5.7%), and gold (5.7%). Conclusions This US database provides multidisciplinary information on pediatric ACD, rates of PPT, and relevant RPPT reactions, validating the high rates of pediatric ACD previously reported in the literature. The registry database is the largest comprehensive collection of US-only pediatric patch test cases on which future research can be built. Continued collaboration between patients, health care providers, manufacturers, and policy makers is needed to decrease the most common allergens in pediatric consumer products.
UR - http://www.scopus.com/inward/record.url?scp=84988647940&partnerID=8YFLogxK
U2 - 10.1097/DER.0000000000000214
DO - 10.1097/DER.0000000000000214
M3 - Article
C2 - 27649353
AN - SCOPUS:84988647940
SN - 1710-3568
VL - 27
SP - 293
EP - 302
JO - Dermatitis
JF - Dermatitis
IS - 5
ER -